Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

被引：6

作者：

Moreno, Carol ^{[1
]}

Greil, Richard ^{[2
]}

Demirkan, Fatih ^{[3
]}

Tedeschi, Alessandra ^{[4
]}

Anz, Bertrand ^{[5
]}

Larratt, Loree ^{[6
]}

Simkovic, Martin ^{[7
]}

Samoilova, Olga ^{[8
]}

Novak, Jan ^{[9
,10
]}

Ben-Yehuda, Dina ^{[11
]}

Strugov, Vladimir ^{[12
]}

Gill, Devinder ^{[13
]}

Gribben, John G. ^{[14
]}

Hsu, Emily ^{[15
]}

Zhou, Cathy ^{[15
]}

Clow, Fong ^{[15
]}

James, Danelle F. ^{[15
]}

Styles, Lori ^{[15
]}

Flinn, Ian W. ^{[16
]}

机构：

[1] Autonomous Univ Barcelona, Hosp Santa Creu St Pau, Barcelona, Spain

[2] Paracelsus Med Univ Salzburg, Canc Cluster Salzburg, Salzburg Canc Res Inst, Salzburg, Austria

[3] Dokuz Eylul Univ, Izmir, Turkey

[4] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[5] Tennessee Oncol, Chattanooga, TN USA

[6] Univ Alberta, Edmonton, AB, Canada

[7] Charles Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic

[8] Nizhny Novogorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[9] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[10] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[11] Hadassah Kerem Med Ctr, Div Hematol, Jerusalem, Israel

[12] Almazov Natl Med Res Ctr, St Petersburg, Russia

[13] Princess Alexandra Hosp, Brisbane, Qld, Australia

[14] Queen Mary Univ London, Barts Canc Inst, London, England

[15] Pharmacycl LLC, Sunnyvale, CA USA

[16] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111370

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

691

引用

页数：4